Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country

Completed

• Conditions: SCLC patients with unresectable stage IIIB or IV by TNM 7th edition who were treated with platinum-based doublet chemotherapy as first line treatment; non small cell lung cancer, prognostic factor, chemotherapy

• Registration Number: TCTR20220131001
• Lead Sponsor: A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-01-31
• Study Start: 2022-01-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 207

Inclusion Criteria

1. confirmed by cytopathology, 2. treated with platinum plus paclitaxel or platinum plus gemcitabine at least 2 cycles (total 4-6 cycles)

Exclusion Criteria

1. ECOG 3-4, 2. planned for radiotherapy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Responder Maximal response after completion of first line chemotherapy RECIST1.0

Secondary Outcome Measures

Name	Time	Method
Overall survival Cut off date 31 Jan 2020 Death date